Option chain shows key data for Coya Therapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Coya Therapeutics.

Coya Therapeutics (NASDAQ:COYA) Stock, Option Chain

COYA THERAPEUTICS INC

Coya Therapeutics

Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.

COYA

Biotech

News

Health Care

Movers

Trading Ideas

General

Coya Therapeutics&#39; Phase 2 study shows monthly LD IL-2 improves cognitive scores and reduces inflammation in Alzheimer&#39;s patients, with no serious adverse events.

Coya Therapeutics&#39; Alzheimer&#39;s Candidate Shows Improved Inflammatory Blood Markers Following Monthly Dosing

Market-Moving Exclusives

Exclusives

Coya Therapeutics advances COYA 303 for inflammatory diseases, combining COYA 301 and GLP-1 RA for a synergistic anti-inflammatory effect.

EXCLUSIVE: Coya Therapeutics Expands Its Pipeline With Combo Therapy For Inflammatory Diseases

pharma lab worker ai

Equities

Coya Therapeutics reports mixed data from Phase 2 study of low-dose IL-2 in Alzheimer&#39;s, showing safety and potential cognitive benefits in q4wks regimen.

Coya Therapeutics&#39; High-Dose Interleukin-2 Misses The Mark In Mid-Stage Alzheimer&#39;s Study

Coya Therapeutics Inc

Press Releases

Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders

Coya Therapeutics to Participate in a Fireside Chat at the 7th Annual Evercore HealthCONx Conference

Coya Therapeutics Provides Enrollment Update of the Investigator-Initiated Phase 1 Study of Low Dose Interleukin-2 (LD IL-2) + CTLA4-Ig Fusion Protein in Patients with Frontotemporal Dementia (FTD)

Coya Therapeutics Announces Pipeline Expansion - COYA 303: COYA 301 in Combination with GLP-1 Receptor Agonist for the Treatment of Inflammatory Diseases

Coya Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Coya Therapeutics Reports Statistically Significant Improvement of Inflammatory Blood Markers in Patients with Alzheimer's Disease Following Monthly Dosing with Low-Dose IL-2, Further Supporting Clinical Development

Coya Therapeutics to Participate in KOL Call Hosted by BTIG to Discuss the Potential Treatment of Alzheimer's Disease Using GLP-1 Agonists and Combinations

Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2024 Financial Results

The Radoff-JEC Group Nominates Three Highly Qualified Candidates for Election to the Atea Pharmaceuticals Board of Directors

Coya Therapeutics Reports Progress from an Academic Supported First-in-Class Treg-derived Exosome Program

ABBV

AVIR

CARM

MEIP

RIBT

SYBX

TSX:PHO

Achieve Life Sciences, Inc. - Common Shares

Achieve Life Sciences

Adverum Biotechnologies, Inc. - Common Stock

Adverum Biotechnologies

Anixa Biosciences

Coherus BioSciences

Editas Medicine

Elicio Therapeutics

Elutia

Enanta Pharmaceuticals, Inc. - Common Stock

Enanta Pharma

EXoZymes

Galectin Therapeutics Inc. - Common Stock

Galectin Therapeutics

Genelux

Immunic

Kyverna Therapeutics, Inc. - Common Stock

Kyverna Therapeutics

Lineage Cell Therapeutics, Inc. Common Stock

Lineage Cell Therapeutics

Lexicon Pharmaceuticals, Inc. - Common Stock

Lexicon Pharmaceuticals

Seres Therapeutics

ProKidney Corp. - Class A Ordinary Shares

ProKidney

Renovaro

Sagimet Biosciences Inc. - Series A Common Stock

Sagimet Biosciences

SELLAS Life Sciences Group, Inc. - Common Stock

SELLAS Life Sciences Gr

Instil Bio

Tiziana Life Sciences Ltd - Common Shares

Tiziana Life Sciences

Tenaya Therapeutics

Vaxart

Zentalis Pharmaceuticals, Inc. - common stock

Comments

Coya Therapeutics

Coya Therapeutics (COYA) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga